HC Wainwright Reiterates Buy Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $50.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2026 earnings at $4.10 EPS, FY2027 earnings at $7.94 EPS and FY2028 earnings at $10.75 EPS.

A number of other brokerages have also recently commented on ATNM. Maxim Group upped their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $25.72.

Actinium Pharmaceuticals Trading Up 4.2 %

Shares of ATNM opened at $7.69 on Monday. The firm has a market cap of $226.09 million, a price-to-earnings ratio of -4.20 and a beta of 0.01. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The firm had revenue of $0.08 million for the quarter. As a group, sell-side analysts predict that Actinium Pharmaceuticals will post -1.87 EPS for the current year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Brandywine Global Investment Management LLC bought a new position in shares of Actinium Pharmaceuticals during the 3rd quarter worth about $1,033,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares during the last quarter. Finally, Sanders Morris Harris LLC acquired a new stake in shares of Actinium Pharmaceuticals in the 1st quarter worth about $78,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.